Originally published by our sister publication Specialty Pharmacy Continuum
By SPC Staff
The FDA approved omaveloxolone (Skyclarys, Reata Pharmaceuticals) as the first treatment for Friedreich’s ataxia.
The drug is indicated for adults and adolescents aged 16 years and older. It is taken orally once a day at a recommended dose of 150 mg. The FDA also granted a Rare Pediatric Disease Priority Review Voucher for omaveloxolone.
Friedreich’s ataxia affects about 5,000